Skip to main content

Catalent Value Stock - Dividend - Research Selection

Catalent

ISIN: US1488061029, WKN: A112H2

Market price date: 05.08.2022
Market price: 110,56 USD


Catalent Fundamental data and company key figures of the share

Annual reports in USD
Key figures 10-02-2022
Cash flow
Net operating cash flow 433.000.000
Capital Expenditures -686.000.000
Free cash flow -253.000.000
Balance sheet
Total Equity 3.915.000.000
Liabilities & Shareholders equity 9.112.000.000
Income statement
Net income 585.000.000
Eps (diluted) 3,110
Diluted shares outstanding 170.000.000
Net sales/revenue 3.998.000.000

Fundamental ratios calculated on: 05-08-2022

Ratios
Key figures 05-08-2022
Cash flow
P/C 43,41
   
P/FC -74,29
Balance sheet
ROI6,42
ROE42,97
Income statement
P/E35,55
Div. Yield0,00%
P/B4,80
P/S4,70


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolCTLT
Market Capitalization18.795.200.512,00 USD
CountryUnited States
IndicesS&P 500
SectorsPharmaceuticals
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.catalent.com


Description of the company

Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.catalent.com


NEWS


Catalent, Inc. Announces Fourth Quarter Fiscal Year 2022 Earnings Conference Webcast

2022-08-08
SOMERSET, N.J. - Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, as... | August 8, 2022

ASRT vs. CTLT: Which Stock Is the Better Value Option?

2022-08-04
ASRT vs. CTLT: Which Stock Is the Better Value Option?

Catalent: Primary Packaging Capability Expansion To Drive Growth

2022-08-04
Expansion of primary packaging capabilities in Japan expected to drive growth for Catalent. Click here to read its growth catalysts, risks and why we assign a Buy rating.

5 Real Growth 'Strong Buys'

2022-08-01
The Seeking Alpha Quant system has its quirks, but it is a great tool to find great holdings. Read more to see five strong buys that I agree with right now.

ClearBridge Mid Cap Growth Strategy Portfolio Manager Commentary Q2 2022

2022-07-31
The ClearBridge Mid Cap Growth Strategy underperformed the Russell Midcap Growth Index during the second quarter. Click here to read the full fund letter.

Stocks making the biggest moves midday: Bausch Health, Meta, Comcast, Qualcomm and more

2022-07-28
These are the stocks posting the largest moves in midday trading.

Comcast earnings beat Wall Street's estimates, reports flat broadband subscribers

2022-07-28
CNBC's 'Squawk Box' team breaks down the latest earnings results from Comcast, which beat analysts' expectations on the top and bottom lines.

Stocks making the biggest moves in the premarket: Stanley Black & Decker, Southwest Airlines, Harley-Davidson and more

2022-07-28
The stocks making the biggest moves in premarket trading include Stanley Black & Decker, Southwest Airlines, Harley-Davidson, and more.

Certara Appoints Rosemary Crane as New Independent Board Member

2022-07-25
PRINCETON, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective July 21, 2022. Her appointment brings the company’s board of directors to eleven members. “We are excited to welcome an accomplished business leader with a proven track record of success join Certara’s Board,” said William F. Feehery, PhD, CEO of Certara. “Rose’s experience in executive leadership

Certara appoints Crane as new independent board member

2022-07-25
Certara (CERT) announced ... CERT, TARS, CTLT, TEVA